In this article, we discuss 5 small-cap stocks to buy according to Ken Fisher. If you want to read our detailed analysis of Fisher’s investment philosophy, hedge fund returns, and history, go directly to 10 Small-Cap Stocks to Buy According to Ken Fisher.
5. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Fisher Asset Management’s Stake Value: $64.8 million
Percentage of Fisher Asset Management’s Portfolio: 0.03%
Market Cap as of June 16: $1.687 billion
The biotechnology company BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) discovers novel, oral, and small-molecule medicines. On June 8, the company’s drug for the prevention of heterotopic ossification (HO) in patients with fibrodysplasia ossificans progressiva (FOP), BCX9250, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
On May 5, Piper Sandler analyst Christopher Raymond maintained an Overweight rating on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) after lowering his price target to $19 to $24.
Out of the 912 hedge funds tracked by Insider Monkey, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was a part of 25 portfolios in the first quarter of 2022. The funds had a total stake worth $458.5 million. In the previous quarter, 19 hedge funds were bullish on the company and had a combined stake value of $412.6 million.